Related Experiment Video

Updated: Aug 19, 2026

RNAi-mediated Control of Aflatoxins in Peanut: Method to Analyze Mycotoxin Production and Transgene Expression in the Peanut/Aspergillus Pathosystem
09:44

RNAi-mediated Control of Aflatoxins in Peanut: Method to Analyze Mycotoxin Production and Transgene Expression in the Peanut/Aspergillus Pathosystem

Published on: December 21, 2015

Microsomal metabolism as a determinant of aflatoxin toxicity

T B Tilak, V Nagarajan, P G Tulpule

    Experientia
    |August 15, 1975
    PubMed

    Insights

    Review of evidence suggests microsomal drug metabolism influences aflatoxin toxicity in rats. Effective metabolism may decrease acute toxicity but yield more carcinogenic byproducts for the rat liver.

    Area of Science:

    • Biochemistry
    • Toxicology
    • Pharmacology

    Background:

    • Microsomal drug-metabolizing systems play a role in xenobiotic detoxification.
    • Aflatoxins are known hepatotoxins and potential carcinogens.

    Purpose of the Study:

    • To review the evidence implicating microsomal drug metabolism in aflatoxin toxicity.
    • To understand the relationship between drug metabolism and aflatoxin's toxic and carcinogenic effects in rats.

    Main Methods:

    • Literature review of studies on drug metabolism and aflatoxin toxicity.
    • Analysis of biochemical pathways involved in aflatoxin metabolism.
    • Evaluation of toxicological and carcinogenic data.

    Main Results:

    • Evidence suggests a role for microsomal drug-metabolizing enzymes in modulating aflatoxin toxicity.
    • Effective drug metabolism appears to reduce acute aflatoxin toxicity in rats.
    • Metabolic products of aflatoxin may be more carcinogenic to rat liver than the parent compound.

    Conclusions:

    • The microsomal drug-metabolizing system is implicated in aflatoxin toxicity.
    • Metabolic activation of aflatoxins can lead to increased carcinogenicity in rat liver.
    • Understanding these metabolic pathways is crucial for assessing aflatoxin risk.

    More Related Videos

    Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

    Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

    Published on: March 28, 2017

    Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.09:21

    Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.

    Published on: February 15, 2019

    Related Concept Videos

    Drug Metabolism: Phase II Reactions01:14

    Drug Metabolism: Phase II Reactions

    Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
    Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs01:21

    Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs

    A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
    The drug's acidity or basicity is essential in determining the metabolic...
    Factors Affecting Drug Biotransformation: Biological01:19

    Factors Affecting Drug Biotransformation: Biological

    Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
    Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
    Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

    In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

    Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...